CRISPR/Cas and Hepatitis B Therapy: Technological Advances and Practical Barriers.
2021
After almost a decade of using CRISPR/Cas9 systems to edit target genes, CRISPR/Cas9 and related technologies are rapidly moving to clinical trials. Hepatitis B virus (HBV), which causes severe liver disease, cannot be cleared by modern antivirals, but represents an ideal target for CRISPR/Cas9 systems. Early studies demonstrated very high antiviral potency of CRISPR/Cas9 and supported its use for developing a cure against chronic HBV infection. This review discusses the key issues that must be solved to make CRISPR/Cas9 an anti-HBV therapy.
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
114
References
0
Citations
NaN
KQI